CNTA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

Open

VWAP

Vol

Mkt Cap

1.01B

Low

Amount

EV/EBITDA(TTM)

Total Shares

6.10B

EV/OCF(TTM)

P/S(TTM)

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Events Timeline

(ET)

2026-06-22

16:30:00

Centessa to be Acquired by Eli Lilly for $38 per Share

2026-06-04 (ET)

2026-06-04

15:00:00

Centessa Pharmaceuticals' Cleminorexton Receives FDA Orphan Designation

2026-04-01 (ET)

2026-04-01

07:40:00

LifeSci Capital Downgrades Centessa to Market Perform After Eli Lilly Acquisition

News

8.5

06-29Yahoo Finance

Eli Lilly Positioned as a Top Stock for Next 3 Years

8.5

06-23NASDAQ.COM

Centessa Pharmaceuticals Acquisition by Eli Lilly Approved by Court

8.5

06-05stocktwits

Pharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs

8.5

06-03CNBC

Eli Lilly Actively Pursuing Acquisition Opportunities

8.5

06-03Newsfilter

Eli Lilly Accelerates Acquisition Strategy Fueled by GLP-1 Drug Success

7.0

05-27Globenewswire

Investor Rights Law Firm Investigates Multiple Companies

13 Analyst Rating

Wall Street analysts forecast CNTA stock price to rise

13 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

27.00

Averages

38.75

High

62.00

Current: 0.000

Low

27.00

Averages

38.75

High

62.00

Wells Fargo

Overweight

Equal Weight

downgrade

$42

AI Analysis

2026-04-20

Reason

Wells Fargo

Price Target

$42

AI Analysis

2026-04-20

downgrade

Overweight

Equal Weight

Reason

Wells Fargo downgraded Centessa (CNTA) to Equal Weight from Overweight with a $42 price target after after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.

Truist

Danielle Brill

Buy

Hold

downgrade

$38

2026-04-12

Reason

Truist

Danielle Brill

Price Target

$38

2026-04-12

downgrade

Buy

Hold

Reason

Truist analyst Danielle Brill downgraded Centessa (CNTA) to Hold from Buy with a $38 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNTA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA.O) is 0.00, compared to its 5-year average forward P/E of -6.15. For a more detailed relative valuation and DCF analysis to assess Centessa Pharmaceuticals PLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.15

Current PE

0.00

Overvalued PE

-2.29

Undervalued PE

-10.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.86

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.01

Undervalued EV/EBITDA

-9.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

261.98

Current PS

313.33

Overvalued PS

1291.01

Undervalued PS

-767.06

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what should my day trade be

Intellectia · 705 candidates

Market Cap: >= 5.00BRegion: USRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

SNAP

Snap Inc

7.77B

INTC

Intel Corp

221.24B

APLS

Apellis Pharmaceuticals Inc

5.14B

Nu Holdings Ltd

69.78B

NIO

NIO Inc

14.97B

AAL

American Airlines Group Inc

7.09B

what stock should I day trade right now

Intellectia · 83 candidates

Price: $10.00 - $80.00Price Change Pct: >= $8.00Relative Vol: >= 3Moving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

APLS

Apellis Pharmaceuticals Inc

2.18B

CNTA

Centessa Pharmaceuticals PLC

4.03B

SNSE

Sensei Biotherapeutics Inc

31.71M

VOR

Vor Biopharma Inc

610.34M

FLY

Firefly Aerospace Inc

3.78B

ALKS

Alkermes Plc

5.02B

yes us market

Intellectia · 87 candidates

Market Cap: >= 2.00BRegion: USBeta: HighRiskList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: $1.00 - $15.00One Week Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

KLAC

KLA Corp

197.49B

AIT

Applied Industrial Technologies Inc

10.53B

ESI

Element Solutions Inc

8.94B

BLTE

Belite Bio Inc

6.98B

XPRO

Expro Group Holdings NV

2.02B

LUNR

Intuitive Machines Inc

3.84B

best stock for swing trade today

Intellectia · 61 candidates

Region: USPrice: $10.00 - $100.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: $5.00 - $15.00One Week Rise Prob: 0 - 100One Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

ZEPP

Zepp Health Corp

327.61M

XPRO

Expro Group Holdings NV

2.07B

FCX

Freeport-McMoRan Inc

94.21B

AGI

Alamos Gold Inc

20.87B

GFI

Gold Fields Ltd

51.00B

VOR

Vor Biopharma Inc

640.24M

stocks predicted to rebound

Intellectia · 14 candidates

Market Cap: >= 1000.00MMoving Average Relationship: PriceCrossAboveMA20One Week Rise Prob: >= 55Macd: bullish

Ticker

Name

Market Cap$

Edwards Lifesciences Corp

46.30B

BEAM

Beam Therapeutics Inc

2.80B

CNTA

Centessa Pharmaceuticals PLC

3.58B

GSAT

Globalstar Inc

7.62B

AUPH

Aurinia Pharmaceuticals Inc

1.90B

CLDX

Celldex Therapeutics Inc

1.62B

best strong buy for today

Intellectia · 86 candidates

Analyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

CING

Cingulate Inc

43.41M

CATX

Perspective Therapeutics Inc

261.77M

ELVN

Enliven Therapeutics Inc

1.51B

ADTN

ADTRAN Holdings Inc

757.90M

UTI

Universal Technical Institute Inc

1.52B

CNTA

Centessa Pharmaceuticals PLC

3.82B

let me seethedaytrading stocks

Intellectia · 41 candidates

Price: $5.00 - $50.00Relative Vol: >= 2Beta: HighRiskWeekly Average Turnover: >= 2,000,000

Ticker

Name

Market Cap$

NEOV

NeoVolta Inc

191.06M

CNTA

Centessa Pharmaceuticals PLC

3.39B

ZURA

Zura Bio Ltd

410.95M

IPI

Intrepid Potash Inc

456.52M

DCOM

Dime Community Bancshares Inc

1.44B

CLBT

Cellebrite DI Ltd

3.85B

today’s stock pick for day trading

Intellectia · 45 candidates

Relative Vol: >= 2Beta: HighRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20Week Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

UAL

United Airlines Holdings Inc

35.92B

KB Financial Group Inc

34.09B

SHG

Shinhan Financial Group Co Ltd

27.59B

HBM

Hudbay Minerals Inc

9.53B

ZION

Zions Bancorporation NA

9.09B

IBRX

Immunitybio Inc

6.82B

which stocks at set up to make big moves

Intellectia · 82 candidates

Relative Vol: >= 1.50Beta: HighRiskWeekly Average Turnover: >= 1,000,000Week Price Change Pct: >= $5.00

Ticker

Name

Market Cap$

GCTK

GlucoTrack Inc

3.56M

TRUE

TrueCar Inc

225.91M

NEOV

NeoVolta Inc

191.06M

LXRX

Lexicon Pharmaceuticals Inc

566.90M

LCII

LCI Industries

3.66B

ELBM

Electra Battery Materials Corporation

97.40M

stocks for quick profit opportunity

Intellectia · 163 candidates

Relative Vol: >= 1.50Beta: HighRiskWeek Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

GCTK

GlucoTrack Inc

3.56M

GORO

Gold Resource Corp

189.27M

TRUE

TrueCar Inc

225.91M

ZENV

Zenvia Inc

47.05M

SCYX

SCYNEXIS Inc

28.05M

NEOV

NeoVolta Inc

191.06M

Whales Holding CNTA

Logos Global Management, L.P.

Deep Track Capital, LP

Farallon Capital Management, L.L.C.

Perceptive Advisors LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Centessa Pharmaceuticals PLC (CNTA) stock price today?

The current price of CNTA is 0 USD — it has increased 0.79

What is Centessa Pharmaceuticals PLC (CNTA)'s business?

What is the price predicton of CNTA Stock?

Wall Street analysts forecast CNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTA is38.75 USD with a low forecast of 27.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.